BioSpace News Archive

Analysis of data over a two-year period finds losing weight and minimizing weight regain can potentially lead to remission of type 2 diabetes

Patient-centered research and clinical studies coupled with device data provide new insights for improving outcomes and quality of life for people living with type 1 diabetes

Study of more than 600 people over 25 years indicates lower blood pressure goals beneficial

Interim clinical data to be presented at ADA 2019 show that approximately 85 percent of patients are insulin-free at six months after Revita DMR outpatient therapy

Study presented at ADA’s Scientific Sessions compared insulin-only mode of iLet to usual care

BioData has announced the roll-out of its Electronic Lab Notebook (ELN) platform, Labguru, with Inserm, France’s only public research institute to focus entirely on human health.

Continuous glucose monitoring demonstrates improved time-in-range, key metabolic datacompared to hybrid closed-loop systems [08-June-2019] MIAMI , June 8, 2019 /PRNewswire/ -- Continuous glucose monitoring (CGM) evaluations in islet transplant recipients who have been insulin independent for an average of 10 years show near-normal glycemic profiles and time-in-range m

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical data from a Phase 2 study of lead product candidate odevixibat (A4250), a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), in biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) were presented today at the 2019 European Society

Leading the mid-Atlantic region in the treatment of Complex Trauma Disorders, Dominion Hospital announced this week that it has opened a new, inpatient TraumaSci unit.

Investigators from the Masonic Medical Research Institute, Weill Cornell Medicine and Beth Israel Deaconess Medical Center have identified the molecular mechanisms by which RAF1 mutations in patients with Noonan Syndrome cause hypertrophic cardiomyopathy, a dangerous thickening of the heart muscle that can lead to heart failure and death.